Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

Inclusion Criteria: * Aged 18-70 years, gender not specified; * Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood); * Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery; * Patients voluntarily choose to undergo microwave ablation therapy or surgical resection. Exclusion Criteria: * Tumor located in the isthmus of the thyroid; * Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid/insular subtype, oncocytic subtype); * Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months); * Pregnant women, lactating women; * Patients with severe coagulation disorders; * Patients with contralateral vocal cord dysfunction; * Patients with contraindications to ultrasound contrast agents; * Other conditions deemed ineligible for enrollment by the investigator.